Latest News

Thursday, June 22, 2017 | Stroke & Cerebrovascular, Visual & Sensory Disturbances

Dysport Approved for Lower Limb Spasticity

The FDA has expanded the indication of Dysport (abobotulinumtoxinA, Ipsen Biopharmaceuticals) to include lower limb spasticity. In a Phase 3 study, adult patients treated with Dysport following a stro…

Read the full story

Wednesday, June 14, 2017 | Movement Disorders, Phase 3/4 Trials, Research and Publications

Phase 3 Results Published for Investigational Levodopa-Induced Dyskinesia Treatment

Results from the Phase 3 EASE LID clinical trial, published online in JAMA Neurology, show that the investigational ADS-5102 (amantadine, Adamas Pharmaceuticals) reduces levodopa-induced dyskinesia (L…

Read the full story

Tuesday, June 13, 2017 | Pain & Headache, Phase 3/4 Trials, Research and Publications

AHS 2017: Amgen’s CGRP Inhibitor Reduces Migraine Days

New Phase 2 data show that Amgen’s investigational investigational CGRP inhibitor erenumab is effective at preventing migraine in patients experiencing 15 or more migraine days per month. In a s…

Read the full story

Monday, June 12, 2017 | Epilepsy & Seizure Disorders

American Epilepsy Society Awards Investigators for Early Career Research

The American Epilepsy Society (AES) has awarded 25 early career scientists and clinicians with fellowships or grants to support their work in epilepsy research. The award recipients include pre-doctor…

Read the full story

Friday, June 09, 2017 | Movement Disorders, Research and Publications

Anti-Alpha-Synuclein Antibody Shows Early Potential as Parkinson’s DMT

PRX002, an investigational monoclonal antibody, may inhibit cell-to-cell transmission of alpha-synuclein and modify disease progression in Parkinson’s disease (PD), according to a study presente…

Read the full story

Thursday, June 08, 2017 | Pain & Headache, Phase 3/4 Trials, Research and Publications

AHS 2017 Meeting: Prochlorperazine More Effective than Hydromorphone for Acute Migraine

A new comparative study presented at the American Headache Society Annual Meeting in Boston shows that that, in patients who visit the emergency department for acute migraine treatment, prochorperazin…

Read the full story

Thursday, June 08, 2017 | Pain & Headache, Phase 3/4 Trials, Research and Publications

AHS 2017 Meeting: Non-Invasive Medical Devices Show Promise for Severe Headaches

Results from studies presented at the American Headache Society Annual Meeting in Boston suggest that non-invasive medical devices offer effective interventions for individuals with migraine. …

Read the full story

Wednesday, June 07, 2017 | Movement Disorders, Research and Publications

Smartphone Sensor Data Offer Insights Into Daily Functioning in Patients with Parkinson’s Disease

Smartphones are a valuable resource in gaining mobility data in patients with Parkinson’s disease, according to new research presented at the 21st International Congress of Parkinson’s Dis…

Read the full story

Thursday, June 01, 2017 | Pain & Headache, Phase 3/4 Trials, Research and Publications

Teva’s Fremanezumab Reduces Monthly Headache Days in Phase 3 Chronic Migraine Study

    Results from the Phase 3 HALO study suggest that fremanezumab (Teva Pharmaceuticals) reduces the number of monthly headache days in patients with chronic migraine. Fremanezumab is …

Read the full story

Tuesday, May 30, 2017 | Dementia & Cognitive Disorders, Movement Disorders, Research and Publications

Neurodegenerative Diseases Linked by Abnormal Proteins Causing Similar Damage to Brain Cells

Abnormal proteins found in Alzheimer's disease, Parkinson's disease, and Huntington's disease share a similar ability to cause damage when they invade brain cells, according to recently pu…

Read the full story

Friday, May 26, 2017 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Research and Publications

NEJM Publishes Phase 3 Data for Epidiolex in Dravet Syndrome as Manufacturer Eyes Mid-2017 NDA Submission

The New England Journal of Medicine has published results from a Phase 3 study showing that Epidiolex (cannabidiol, GW Pharmaceuticals) reduces monthly convulsive seizure frequency compared to placebo…

Read the full story

Tuesday, May 23, 2017 | Neuromuscular & Immune Disorders, Phase 3/4 Trials, Research and Publications

Celgene’s Investigational MS Agent Reduces Annual Relapse Rate but Falls Short of Disability Endpoint in Phase 3 Trial

New Phase 3 findings suggest that Celgene’s investigational ozanimod for relapsing multiple sclerosis (MS) reduces annualized relapse rate in a clinically meaningful way but does not significant…

Read the full story

Friday, May 19, 2017 | Pain & Headache, Research and Publications

Migraine Prevalence Higher in Collegiate Athletes, New Study Finds

New findings suggest that collegiate athletes have an increased prevalence of migraines, with female athletes being particularly affected. In a retrospective cross-section survey, researchers evaluate…

Read the full story

Tuesday, May 16, 2017 | Product Launches and Updates, Research and Publications, Stroke & Cerebrovascular

Endovascular Intervention Found Effective for "Late Window" Stroke Patients: DAWN Trial Analysis

The window for reducing disability and improving functional independence in stroke patients receiving endovascular therapy could extend as far as 24 hours, according to preliminary results from the DA…

Read the full story

Tuesday, May 16, 2017 |

Endovascular Intervention Found Effective for “Late Window” Stroke Patients: DAWN Trial Analysis

The window for reducing disability and improving functional independence in stroke patients receiving endovascular therapy could extend as far as 24 hours, according to preliminary results from the DA…

Read the full story
Load More